Eticovo

Digital Pharmacist

The RxWiki Digital Pharmacist stamp of approval lets you know that this content has been created and reviewed by a licensed pharmacist.

Eticovo is used to treat 5 inflammatory conditions including rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, plaque psoriasis, ankylosing spondylitis, and psoriatic arthritis.

Eticovo Overview

Reviewed: May 8, 2019
Updated: 

Eticovo is a prescription medication used to treat inflammatory conditions including moderate to severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis in adults. Eticovo is also used to treat juvenile idiopathic arthritis and children with chronic moderate-to-severe plaque psoriasis.

Eticovo belongs to a group of drugs called tumor-necrosis factor (TNF) inhibitors which reduce the effect of TNF in the body and block the damage that too much TNF can cause.

This medication comes in an injectable form in a pre-filled, single-dose syringe in two different concentrations: 2 mg/0.5 ml and 50 mg/1 ml. Eticovo is injected under the skin (subcutaneously), once or twice a week, depending on the diagnosis.

Common side effects include redness or pain at the injection site and upper respiratory infections. 

How was your experience with ?

First, a little about yourself

Tell us about yourself in a few words?

What tips would you provide a friend before taking ?

What are you taking for?

Choose one
  • Other

How long have you been taking it?

Choose one
  • Less than a week
  • A couple weeks
  • A month or so
  • A few months
  • A year or so
  • Two years or more

How well did work for you?

Did you experience many side effects while taking this drug?

How likely would you be to recommend to a friend?

Eticovo Drug Class

Back to Top

Eticovo is part of the drug class:

Eticovo FDA Warning

Back to Top

WARNING: SERIOUS INFECTIONS and MALIGNANCIES

SERIOUS INFECTIONS
Patients treated with etanercept products are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions (5.1) and Adverse Reactions (6)]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

Eticovo should be discontinued if a patient develops a serious infection or sepsis.

Reported infections include:

  • Active tuberculosis, including reactivation of latent tuberculosis. Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent tuberculosis before Eticovo use and during therapy. Treatment for latent infection should be initiated prior to Eticovo use.

  • Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness.

  • Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.

The risks and benefits of treatment with Eticovo should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.

Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with Eticovo, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.

MALIGNANCIES
Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including etanercept products.